Clair: Stanford-Developed Continuous Hormone Monitoring Wearable with 10 Biosensors

A wrist-worn wearable from a Stanford spinout that uses 10 biosensors and AI to estimate estrogen, progesterone, LH, and FSH levels in real time without blood draws, achieving 94.1% cycle phase classification accuracy and 87% LH surge detection sensitivity across 127 menstrual cycles.

Presented By Our Partners

Reproductive hormones govern far more than fertility. Estrogen, progesterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) influence cardiovascular function, bone density, cognitive performance, mood regulation, sleep architecture, and metabolic health throughout a woman’s life. Yet monitoring these hormones has traditionally required blood draws, urine test strips, or saliva kits, all point-in-time measurements that capture a single moment rather than the continuous fluctuations that characterize hormonal physiology. A 2023 review published in Nature Reviews Endocrinology by Mauvais-Jarvis et al. established that the temporal dynamics of hormonal fluctuations, not just absolute levels, drive many of the physiological effects that women experience across their menstrual cycles, during perimenopause, and beyond (DOI: 10.1038/s41574-023-00872-3).

A 2022 study published in Digital Biomarkers by Goodale et al. demonstrated that multi-sensor wearable data, including skin temperature, heart rate variability, and electrodermal activity, can predict menstrual cycle phases with meaningful accuracy when processed through machine learning algorithms, suggesting that hormonal states leave detectable physiological signatures in continuously measurable biosignals (DOI: 10.1159/000525241). Clair Health, a Stanford-founded startup, has built on this research foundation to develop the first wearable device designed specifically for continuous hormone inference from wrist-based biosensors.

What Is the Clair Wearable?

Clair is a wrist-worn health device developed by Clair Health, founded by Stanford engineers Jenny Duan and Abhinav Agarwal, that uses 10 integrated biosensors and AI algorithms to estimate reproductive hormone levels in real time without blood draws, urine tests, or any invasive measurement. The device tracks skin temperature, heart rate, heart rate variability, respiratory rate, electrodermal activity (a measure of autonomic arousal via sweat gland activity), and sleep metrics, then processes these signals through proprietary machine learning models to infer levels of estrogen, progesterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH).

The core insight behind Clair’s approach is that hormonal fluctuations produce detectable downstream effects on multiple physiological systems simultaneously. Estrogen affects thermoregulation, cardiovascular tone, and skin conductance. Progesterone elevates basal body temperature and modulates respiratory drive. LH surges produce measurable changes in autonomic function. By combining signals from 10 sensors rather than relying on any single biomarker, Clair’s AI can triangulate hormonal status with a level of accuracy that single-sensor approaches cannot achieve.

The wearable connects to a companion mobile app where all data processing occurs on the user’s phone rather than in external cloud servers, a privacy-first architecture that keeps sensitive health data under the user’s direct control. The app presents hormone estimates, cycle phase identification, fertility windows, and personalized insights derived from the continuous biosensor data.

Clair has tested its technology on more than 40 women across 127 menstrual cycles, generating over 5,000 days of data. The company reports 94.1% accuracy in classifying menstrual cycle phase from wearable signals and 87% sensitivity in detecting LH surges with timing accuracy within 1.2 days. The device is expected to ship in November 2026, and Clair intends to pursue FDA approval through a clinical trial at Stanford Medicine.

The Science Behind Non-Invasive Hormone Inference

Traditional hormone measurement requires accessing biological fluids (blood, urine, saliva) that contain the hormones directly. Non-invasive hormone inference takes a fundamentally different approach: instead of measuring the hormones themselves, it measures the physiological effects that hormones produce on systems accessible to wearable sensors.

This approach rests on well-established endocrinological principles. Estrogen modulates thermoregulatory setpoints, vascular tone (affecting heart rate and heart rate variability), and sympathetic nervous system activity (affecting electrodermal activity). Progesterone raises basal body temperature by 0.3 to 0.5 degrees Celsius in the luteal phase and affects respiratory rate. LH surges produce autonomic shifts that alter cardiovascular and electrodermal parameters. FSH changes during the follicular phase correlate with specific physiological signatures.

The challenge is that each of these physiological parameters is also influenced by non-hormonal factors: exercise, stress, caffeine, ambient temperature, sleep quality, and illness all affect heart rate, skin temperature, and electrodermal activity. Clair’s multi-sensor approach addresses this challenge through sensor fusion: by combining data from 10 sensors simultaneously, the AI can distinguish hormonal signals from confounding influences because hormones produce correlated changes across multiple systems simultaneously, while most confounders affect individual parameters independently.

The 94.1% cycle phase classification accuracy and 87% LH surge detection sensitivity reported by Clair represent strong performance for a non-invasive approach, though it is important to note that these results were obtained in a research setting with controlled protocols. Real-world accuracy may differ due to lifestyle variability, individual physiological differences, and the diversity of populations not fully represented in the initial 40-participant study.

What the Clair Wearable Does Well

The 10-sensor fusion approach is Clair’s strongest technical differentiator. Most wearables that offer cycle tracking rely on a single primary signal, usually temperature (Oura, Apple Watch) or a combination of temperature and heart rate. Clair’s integration of electrodermal activity, respiratory rate, and additional sensor modalities creates a richer physiological dataset that supports more nuanced hormone inference than temperature alone can provide.

The non-invasive continuous monitoring paradigm transforms hormone tracking from periodic snapshots into longitudinal curves. Understanding how estrogen and progesterone change throughout the cycle, rather than checking at a single time point, provides a fundamentally more informative picture of hormonal health. This is particularly valuable for identifying subtle abnormalities such as anovulatory cycles, luteal phase defects, or hormonal patterns associated with conditions like PCOS.

The on-device processing architecture (data processed on the user’s phone, not in cloud servers) addresses a critical privacy concern. Reproductive health data is among the most sensitive personal information, and the legal landscape around reproductive health data has become increasingly complex. Clair’s privacy-first design minimizes data exposure risk.

The Stanford research pedigree and planned clinical trial at Stanford Medicine provide academic credibility that distinguishes Clair from consumer products making similar claims without clinical validation.

The multi-hormone coverage (estrogen, progesterone, LH, FSH) from a single wearable device replaces what would otherwise require multiple blood draws across the cycle or daily use of urine-based hormone test strips.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Pricing, Access, and Practical Realities

Clair is expected to ship in November 2026. Pricing has not been officially announced. Given the device’s 10-sensor hardware, Stanford-backed technology, and positioned comparison to medical hormone testing, pricing is likely to fall in the premium wearable range ($300 to $500+), though this is speculative.

For context, LH test strips (Clearblue, Easy@Home) cost $20 to $50 per cycle for daily testing during the fertile window. Blood-based hormone panels cost $100 to $300 per draw and provide only point-in-time measurements. Continuous hormone monitoring services using multiple blood draws across a cycle (such as those offered by some fertility clinics) can cost $500 to $1,500 per cycle. If Clair’s estimates prove sufficiently accurate, a one-time device purchase could replace ongoing testing costs.

The device requires consistent wearing for optimal accuracy, as the AI models depend on continuous data streams to distinguish hormonal signals from confounders. Gaps in wear create data gaps that may reduce the quality of hormone estimates.

FDA approval status is pending. Clair intends to pursue FDA clearance through a clinical trial at Stanford Medicine, but the timeline for regulatory approval is uncertain. Until FDA clearance is obtained, the device cannot be marketed as a diagnostic tool for fertility planning or medical hormone monitoring.

Who It Is Best For

Clair is best suited for women who want continuous insight into their hormonal patterns for fertility awareness, cycle optimization, or hormonal health monitoring without the inconvenience and cost of repeated blood draws or daily urine testing. Women actively trying to conceive who want to identify their fertile window through LH surge detection without daily test strips represent a primary audience.

Women with irregular cycles or suspected hormonal conditions (PCOS, luteal phase deficiency, anovulation) who want longitudinal hormonal data to share with their healthcare providers may find Clair’s continuous monitoring more informative than periodic blood tests.

Athletes and performance-oriented women who want to align training, nutrition, and recovery strategies with their hormonal cycle phase can use Clair’s real-time hormone estimates to optimize their approach across follicular and luteal phases.

Women approaching perimenopause who want to track changing hormonal patterns as FSH rises and estrogen becomes irregular may find continuous monitoring valuable for understanding their transition.

The device is less suited for women who need clinically validated hormone measurements for medical decisions (until FDA clearance is obtained), or for those who prefer a simpler wearable experience without hormone-specific analytics.

How It Compares

Against the Oura Ring 4 ($349 + subscription), which estimates menstrual cycle phase primarily from temperature, Clair uses 10 sensors for multi-hormone inference rather than temperature-based cycle tracking alone. Oura identifies cycle phases; Clair aims to estimate actual hormone levels. Oura is a general-purpose health ring with cycle tracking as one feature; Clair is purpose-built for hormone monitoring.

Against the Apple Watch cycle tracking feature (included in various Apple Watch models), Clair offers dedicated multi-sensor hormone inference versus Apple’s temperature-based period prediction. Apple provides broader smartwatch functionality; Clair provides deeper hormonal insight.

Against LH test strips (Clearblue, Easy@Home, $20 to $50/cycle), Clair offers continuous monitoring versus daily point-in-time testing, and estimates multiple hormones versus LH alone. Test strips provide direct measurement of urinary LH; Clair provides inference from physiological signals.

Against blood-based hormone panels ($100 to $300 per draw), Clair offers non-invasive continuous estimates versus accurate but infrequent direct measurement. Blood tests remain the gold standard for hormone measurement accuracy; Clair trades precision for continuity and convenience.

Limitations and Open Questions

The fundamental limitation of non-invasive hormone inference is that it measures downstream effects rather than the hormones themselves. While Clair’s multi-sensor approach and AI processing achieve impressive accuracy in research conditions (94.1% cycle phase classification, 87% LH surge detection), these are inferential estimates, not direct measurements. Individual accuracy may vary based on factors that affect the physiological signals used for inference: fitness level, medication use, chronic conditions, stress levels, and body composition.

The 40-participant, 127-cycle validation dataset is a strong start but represents a limited population. Accuracy across diverse age groups, ethnicities, body types, and health conditions requires validation in larger studies. The planned Stanford Medicine clinical trial should help address this gap.

The 87% LH surge detection sensitivity with 1.2-day timing accuracy is clinically meaningful but not sufficient for time-critical fertility planning where a 1-day error could mean missing the fertile window. Women using the device for conception timing should consider supplementing with traditional LH test strips during critical windows until Clair’s accuracy is further validated.

FDA clearance is pending and not guaranteed. The regulatory pathway for a device that infers hormone levels from proxy signals (rather than measuring them directly) is novel and may face scrutiny regarding the strength of clinical evidence required.

The November 2026 ship date places the device months away from consumer availability, and development timelines in health technology frequently extend. Early adopters should prepare for potential delays.

What This Means for Your Health

Hormonal health is one of the least accessible dimensions of personal health monitoring. Blood hormone panels require medical orders, clinic visits, and significant cost, and provide only momentary snapshots of a continuously fluctuating system. A wearable that can provide continuous hormone estimates non-invasively would democratize access to hormonal health information that has historically required clinical infrastructure.

Within Healthcare Discovery‘s Five Pillars framework, hormonal health crosscuts all five pillars. Estrogen and progesterone influence Sleep architecture and quality. Hormonal fluctuations affect exercise performance, recovery, and injury risk (Movement). Cycle-phase nutrition optimization is an emerging area of sports and metabolic science (Nutrition). Hormonal shifts modulate stress reactivity and autonomic balance (Breathwork). And the psychological impact of hormonal fluctuations on mood, cognition, and emotional resilience connects directly to Mindset.

Clair represents a broader trend in health technology: moving from symptom tracking (recording what happened) to physiological inference (understanding why it happened). By providing estimated hormone levels alongside the symptoms and behavioral patterns they drive, Clair aims to give women causal insight into their health rather than correlational data alone.

If the Stanford clinical trial confirms the accuracy reported in preliminary studies and FDA clearance follows, Clair could establish a new category of consumer health device that makes hormonal health as accessible and continuously monitored as heart rate and step count.

Frequently Asked Questions

What is the Clair wearable?
Clair is a wrist-worn device from a Stanford spinout that uses 10 biosensors and AI to estimate reproductive hormone levels (estrogen, progesterone, LH, FSH) in real time without blood draws. It achieves 94.1% cycle phase classification accuracy and 87% LH surge detection sensitivity based on research data from 127 menstrual cycles.

How much will Clair cost?
Pricing has not been officially announced. The device is expected to ship in November 2026. Given its 10-sensor technology and Stanford-backed development, pricing is anticipated in the premium wearable range.

How does Clair track hormones without blood?
Clair measures 10 physiological signals (skin temperature, heart rate, HRV, respiratory rate, electrodermal activity, sleep data, and others) that are affected by hormone levels. AI algorithms process these signals simultaneously to infer hormone concentrations, leveraging the principle that hormonal changes produce correlated shifts across multiple body systems.

Is Clair FDA approved?
Not yet. Clair intends to pursue FDA approval through a clinical trial at Stanford Medicine. Until clearance is obtained, the device is a consumer wellness product providing hormone estimates, not FDA-validated diagnostic measurements.

Can Clair replace fertility testing?
Clair’s 87% LH surge detection sensitivity with 1.2-day timing accuracy is promising but not yet sufficient to replace clinical fertility testing for time-critical conception planning. Women using Clair for fertility awareness should consider supplementing with traditional LH test strips during critical windows until accuracy is further validated.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.